‘Screen-and-treat’ scheme for hepatitis B may prevent deadly complications
Worldwide, 400 million people are living with hepatitis B virus (HBV) or hepatitis C virus (HCV) infection. These chronic infections are responsible for more than half of all cases of liver cirrhosis and nearly three quarters of cases of primary liver cancer.
In a ceremony attended by senior representatives of the Waters Corporation, Imperial College London, The Gambia Government and the MRC Unit The Gambia, a Waters Xevo TQ MS mass spectrometer was donated to The Unit on 28th May 2012.
Partners in the Prevention of Liver Fibrosis and Cancer in Africa consortium – Prolifica – met in The Gambia recently for a two day kick off meeting. Funded by the European Commission, Prolifica has brought together investigators from The Gambia , Senegal, Nigeria, the UK, Italy and France.